sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
15-Sep-2014 05:39
US Eastern Time




Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books



Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation


Submit a Calendar Item


Links & Resources


RSS Feeds

Accessibility Option On


Portal Home


Background Articles

Research Papers


Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 876-881 out of 881.

<< < 31 | 32 | 33 | 34 | 35 | 36

Public Release: 20-Sep-2012
New strategies needed to combat disease in developing countries
So-called lifestyle diseases are gaining ground with epidemic speed in low-income countries. The traditional health focus in these countries has been to combat communicable diseases such as malaria, HIV and tuberculosis. However, research from the University of Copenhagen suggests that dividing campaigns into combating either non-communicable or communicable diseases is ineffective and expensive. A new article by Danish scientists published in the well-reputed journal Science provides an overview.

Contact: Professor Ib Bygbjerg
University of Copenhagen

Public Release: 20-Sep-2012
Sanofi and TB Alliance announce collaboration to accelerate new tuberculosis treatments
Sanofi and the Global Alliance for TB Drug Development announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis, a deadly infectious disease that resulted in almost 1.5 million deaths worldwide in 2010. Under the agreement, Sanofi and TB Alliance will collaborate to further optimize and develop several novel compounds in Sanofi's library that have demonstrated activity against Mycobacterium tuberculosis, the bacterium that causes TB.

Contact: Derek Ambrosino
TB Alliance

Public Release: 19-Sep-2012
Science Translational Medicine
BIDMC and Diagnostics For All create first low-cost, paper-based, point of care liver function test
A new postage stamp-sized, paper-based device could provide a simple and reliable way to monitor for liver damage at a cost of only pennies per test, say researchers at Beth Israel Deaconess Medical Center (BIDMC) and Diagnostics For All (DFA), a Cambridge, MA nonprofit dedicated to improving the health of people living in the developing world.
Department of Defence, National Institutes of Health, Gates Foundation

Contact: Kelly Lawman
Beth Israel Deaconess Medical Center

Public Release: 19-Sep-2012
Autism symptoms could arise from unreliable neural responses
Diverse symptoms associated with autism could be explained by unreliable activity of neurons in the brain in response to basic, nonsocial sensory information, according to a study published by Cell Press on September 19th in the journal Neuron. The new findings suggest that autism is a disorder of general neural processing and could potentially provide an explanation for the origins of a range of psychiatric and neurological disorders.

Contact: Elisabeth (Lisa) Lyons
Cell Press

Public Release: 17-Sep-2012
Diabetes Care
Risk of developing diabetes higher in neighborhoods that aren't walk-friendly: Study
Whether your neighborhood is conducive to walking could determine your risk for developing diabetes, according to a new study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences.

Contact: Kate Taylor
St. Michael's Hospital

Public Release: 17-Sep-2012
EMBO Molecular Medicine
Scientists reveal how natural antibiotic kills tuberculosis bacterium
A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, works. This promising drug candidate is active against many of the drug-resistant types of the tuberculosis bacterium that no longer respond to treatment with the front-line drug isoniazid.

Contact: Barry Whyte

Showing releases 876-881 out of 881.

<< < 31 | 32 | 33 | 34 | 35 | 36